US Population Eligibility and Estimated Impact of Semaglutide Treatment on Obesity Prevalence and Cardiovascular Disease Events
Open Access
- 14 August 2023
- journal article
- research article
- Published by Springer Nature in Cardiovascular Drugs and Therapy
- Vol. 39 (1) , 75-84
Abstract
Background: Semaglutide 2.4 mg benefits weight loss and reduction of cardiovascular disease (CVD) risk factors in adults with obesity. We estimated the US population eligibility for semaglutide 2.4 mg (based on the weight management indication) and the impact on obesity and CVD events. Methods: We applied STEP 1 trial eligibility criteria to US adults aged ≥ 18 years in the US National Health and Nutrition Examination Survey (NHANES) 2015-2018 to estimate the US eligible population. Semaglutide weight changes in STEP 1 were applied to estimate the population impact on weight changes and obesity prevalence. We also estimated 10-year CVD risks utilizing the BMI-based Framingham CVD risk scores. The difference in estimated risks with and without semaglutide “treatment” multiplied by the eligible NHANES weighted population represented the estimated “preventable” CVD events. Results: We identified 3999 US adults weighted to an estimated population size of 93.0 million [M] (38% of US adults) who fit STEP 1 eligibility criteria. Applying STEP 1 treatment effects on weight loss resulted in an estimated 69.1% (64.3 M) and 50.5% (47.0 M) showing ≥ 10% and ≥ 15% weight reductions, respectively, translating to a 46.1% (43.0 M) reduction in obesity (BMI ≥ 30 kg/m2) prevalence. Among those without CVD, estimated 10-year CVD risks were 10.15% “before” and 8.34% “after” semaglutide “treatment” reflecting a 1.81% absolute (and 17.8% relative) risk reduction translating to 1.50 million preventable CVD events over 10 years. Conclusion: Semaglutide treatment in eligible US adults may substantially reduce obesity prevalence and CVD events, which may dramatically impact associated healthcare costs.Keywords
Funding Information
- Novo Nordisk
This publication has 20 references indexed in Scilit:
- Projected U.S. State-Level Prevalence of Adult Obesity and Severe ObesityNew England Journal of Medicine, 2019
- The Discovery and Development of Liraglutide and SemaglutideFrontiers in Endocrinology, 2019
- Efficacy of High-Dose Liraglutide as an Adjunct for Weight Loss in Patients with Prior Bariatric SurgeryObesity Surgery, 2018
- Real-world use and modeled impact of glucose-lowering therapies evaluated in recent cardiovascular outcomes trials: An NCDR® Research to Practice projectEuropean Journal of Preventive Cardiology, 2017
- Health Effects of Overweight and Obesity in 195 Countries over 25 YearsNew England Journal of Medicine, 2017
- Liraglutide and Cardiovascular Outcomes in Type 2 DiabetesNew England Journal of Medicine, 2016
- A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight ManagementNew England Journal of Medicine, 2015
- 2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in AdultsJACC, 2014
- General Cardiovascular Risk Profile for Use in Primary CareCirculation, 2008
- Validity of Self-reported Diagnoses Leading to Hospitalization: A Comparison of Self-reports with Hospital Records in a Prospective Study of American AdultsAmerican Journal of Epidemiology, 1998